

## 5.70.069

---

|                    |                            |                              |                 |
|--------------------|----------------------------|------------------------------|-----------------|
| <b>Section:</b>    | Prescription Drugs         | <b>Effective Date:</b>       | January 1, 2026 |
| <b>Subsection:</b> | Analgesics and Anesthetics | <b>Original Policy Date:</b> | June 22, 2018   |
| <b>Subject:</b>    | Olumiant                   | <b>Page:</b>                 | 1 of 10         |

---

**Last Review Date:** December 12, 2025

---

## Olumiant

### Description

#### Olumiant (baricitinib)

---

### Background

Olumiant (baricitinib) is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes or hematopoiesis and immune cell function. Janus kinase inhibitors inhibit one or more Janus family of enzymes (JAK1, JAK2, JAK3, TYK2), interfering with the JAK-STAT signaling pathway. Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. Olumiant modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs (1).

The use of Olumiant for the treatment of COVID-19 should be billed under the medical benefit.

The use of Olumiant for the treatment of alopecia areata is excluded from coverage.

### Regulatory Status

FDA-approved indications: Olumiant is a Janus kinase (JAK) inhibitor indicated for: (1)

- the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers.
  - Limitations of Use: Olumiant should not be used in combination with other JAK inhibitors, biological DMARDs or potent immunosuppressants such as azathioprine and cyclosporine.

---

|                    |                            |                              |                 |
|--------------------|----------------------------|------------------------------|-----------------|
| <b>Section:</b>    | Prescription Drugs         | <b>Effective Date:</b>       | January 1, 2026 |
| <b>Subsection:</b> | Analgesics and Anesthetics | <b>Original Policy Date:</b> | June 22, 2018   |
| <b>Subject:</b>    | Olumiant                   | <b>Page:</b>                 | 2 of 10         |

---

- the treatment of COVID-19 in hospitalized adult patients requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO.
- the treatment of adult patients with severe alopecia areata.
  - Limitations of Use: Olumiant should not be used in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine, or other potent immunosuppressants.

In addition, the FDA has approved the emergency use of Olumiant for the treatment of COVID-19 in hospitalized pediatric patients (2).

Olumiant carries several boxed warnings: (1)

1. Serious infections
  - a. Increased risk for serious infections, including tuberculosis and bacterial, invasive fungi, viral and other opportunistic infections that may lead to hospitalization. If a serious infection develops, interrupt Olumiant until the infection is controlled. Prior to the initiation of Olumiant, a test for latent tuberculosis must be conducted. If the test is positive, start treatment for tuberculosis prior to starting Olumiant. Monitor all patients for active tuberculosis during treatment, even if the initial latent tuberculosis test is negative.
2. Mortality
  - a. RA patients 50 years of age and older with at least one cardiovascular risk factor showed a higher rate of all-cause mortality, including sudden cardiovascular death, in patients treated with JAK inhibitors compared to TNF blockers.
3. Malignancies
  - a. Lymphoma and other malignancies have been observed in patients treated with Olumiant.
  - b. In RA patients treated with a JAK inhibitor, a higher rate of malignancies was observed when compared with TNF blockers.
4. Major adverse cardiovascular events (MACE)
  - a. RA patients 50 years of age and older with at least one cardiovascular risk factor treated with a JAK inhibitor showed a higher rate of MACE (defined as cardiovascular death, myocardial infarction, and stroke) when compared to TNF blockers. Patients who are current or past smokers are at increased risk. Olumiant should be discontinued in patients that have experienced a myocardial infarction or stroke.
5. Thrombosis

---

|                    |                            |                              |                 |
|--------------------|----------------------------|------------------------------|-----------------|
| <b>Section:</b>    | Prescription Drugs         | <b>Effective Date:</b>       | January 1, 2026 |
| <b>Subsection:</b> | Analgesics and Anesthetics | <b>Original Policy Date:</b> | June 22, 2018   |
| <b>Subject:</b>    | Olumiant                   | <b>Page:</b>                 | 3 of 10         |

---

- a. Thrombosis, including deep vein thrombosis, pulmonary embolism, and arterial thrombosis, have occurred in patients treated with Olumiant. Many of these adverse events were serious and some resulted in death.
- b. In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with a JAK inhibitor, a higher rate of thrombosis was observed when compared with TNF blockers.

The safety and effectiveness of Olumiant in pediatric patients have not been established (1).

---

## Related policies

Rinvoq, Xeljanz/XR

### Policy

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

Olumiant may be considered **medically necessary** if the conditions indicated below are met.

Olumiant may be considered **investigational** for all other indications.

## Prior-Approval Requirements

***The use of Olumiant for the treatment of COVID-19 should be billed under the medical benefit.***

**Age** 18 years of age or older

## Diagnosis

Patient must have **ONE** of the following with provided documentation (e.g., medical records, laboratory reports):

1. Moderately to severely active rheumatoid arthritis (RA)
  - a. Inadequate treatment response, intolerance, or contraindication to a 3-month trial of at least **ONE** conventional disease-modifying antirheumatic drug (DMARD) (see Appendix 1)

---

|                    |                            |                              |                 |
|--------------------|----------------------------|------------------------------|-----------------|
| <b>Section:</b>    | Prescription Drugs         | <b>Effective Date:</b>       | January 1, 2026 |
| <b>Subsection:</b> | Analgesics and Anesthetics | <b>Original Policy Date:</b> | June 22, 2018   |
| <b>Subject:</b>    | Olumiant                   | <b>Page:</b>                 | 4 of 10         |

---

- b. Inadequate treatment response, intolerance, or contraindication to at least **ONE** TNF blocker (e.g., Cimzia, Enbrel, Humira, Remicade, Simponi/Simponi Aria)
- c. Patient **MUST** have tried the preferred product(s) (see Appendix 2) unless the patient has a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication)

**AND ALL** of the following:

- a. Prescriber has considered the risks for malignancy and major adverse cardiovascular events (MACE) (e.g., advanced age, smoking history, cardiovascular risk factors etc.) and determined that Olumiant therapy is appropriate
- b. Result for latent TB infection is negative **OR** result was positive for latent TB and patient completed treatment (or is receiving treatment) for latent TB

**AND NONE** of the following:

- a. Active bacterial, invasive fungal, viral, and other opportunistic infections
- b. Severe hepatic impairment
- c. A lymphocyte count less than 500 cells/mm<sup>3</sup>
- d. An absolute neutrophil count less than 1000 cells/mm<sup>3</sup>
- e. A hemoglobin less than 8 g/dL
- f. History of thrombotic events including deep vein thrombosis (DVT) or pulmonary embolism (PE)
- g. Used in combination with any other biologic DMARD or targeted synthetic DMARD (see Appendix 1)
- h. Used in combination with potent immunosuppressants azathioprine or cyclosporine
- i. Given concurrently with live vaccines

All approved requests are subject to review by a clinical specialist for final validation and coverage determination once all required documentation has been received. Current utilization, including samples, does not guarantee approval of coverage.

---

## Prior-Approval Renewal Requirements

*The use of Olumiant for the treatment of COVID-19 should be billed under the medical benefit.*

**Age** 18 years of age or older

---

|                    |                            |                              |                 |
|--------------------|----------------------------|------------------------------|-----------------|
| <b>Section:</b>    | Prescription Drugs         | <b>Effective Date:</b>       | January 1, 2026 |
| <b>Subsection:</b> | Analgesics and Anesthetics | <b>Original Policy Date:</b> | June 22, 2018   |
| <b>Subject:</b>    | Olumiant                   | <b>Page:</b>                 | 5 of 10         |

---

## Diagnosis

Patient must have **ONE** of the following with provided documentation (e.g., medical records, laboratory reports):

1. Rheumatoid arthritis (RA)
  - a. Patient **MUST** have tried the preferred product(s) (see Appendix 2) unless the patient has a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication)

**AND ALL** of the following:

1. Condition has improved or stabilized
2. Prescriber has considered the risks for malignancy and major adverse cardiovascular events (MACE) (e.g., advanced age, smoking history, cardiovascular risk factors etc.) and determined that continuation of Olumiant therapy is appropriate

**AND NONE** of the following:

1. Active bacterial, invasive fungal, viral, and other opportunistic infections
2. Used in combination with any other biologic DMARD or targeted synthetic DMARD (see Appendix 1)
3. Used in combination with potent immunosuppressants azathioprine or cyclosporine
4. Development of thrombotic events (including DVTs or PEs)
5. Given concurrently with live vaccines

All approved requests are subject to review by a clinical specialist for final validation and coverage determination once all required documentation has been received. Current utilization, including samples, does not guarantee approval of coverage.

## Policy Guidelines

### Pre-PA Allowance

None

### Prior-Approval Limits

---

|                    |                            |                              |                 |
|--------------------|----------------------------|------------------------------|-----------------|
| <b>Section:</b>    | Prescription Drugs         | <b>Effective Date:</b>       | January 1, 2026 |
| <b>Subsection:</b> | Analgesics and Anesthetics | <b>Original Policy Date:</b> | June 22, 2018   |
| <b>Subject:</b>    | Olumiant                   | <b>Page:</b>                 | 6 of 10         |

---

**Quantity** 4 mg per day

**Duration** 12 months

### **Prior-Approval Renewal Limits**

**Quantity** 4 mg per day

**Duration** 18 months

#### **Rationale**

#### **Summary**

Olumiant (baricitinib) is indicated for the treatment of adult patients with rheumatoid arthritis (RA), for the treatment of COVID-19 in hospitalized patients, and for the treatment of adults with severe alopecia areata. Olumiant has several boxed warnings including increased risk for: serious infections, mortality, malignancies, MACE, and thrombosis. The safety and effectiveness of Olumiant in pediatric patients have not been established (1).

The use of Olumiant for the treatment of COVID-19 should be billed under the medical benefit.

The use of Olumiant for the treatment of alopecia areata is excluded from coverage.

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Olumiant while maintaining optimal therapeutic outcomes.

#### **References**

1. Olumiant [package insert]. Indianapolis, IN: Lilly USA, LLC; June 2022.
2. Baricitinib EUA Letter of Authorization. May 2022. Available at: [https://www.fda.gov/media/143822/download?utm\\_medium=email&utm\\_source=govdelivery](https://www.fda.gov/media/143822/download?utm_medium=email&utm_source=govdelivery)

#### **Policy History**

| Date           | Action                  |
|----------------|-------------------------|
| June 2018      | Addition to PA          |
| September 2018 | Annual editorial review |

---

|                    |                            |                              |                 |
|--------------------|----------------------------|------------------------------|-----------------|
| <b>Section:</b>    | Prescription Drugs         | <b>Effective Date:</b>       | January 1, 2026 |
| <b>Subsection:</b> | Analgesics and Anesthetics | <b>Original Policy Date:</b> | June 22, 2018   |
| <b>Subject:</b>    | Olumiant                   | <b>Page:</b>                 | 7 of 10         |

---

|                |   |
|----------------|---|
|                | Addition of requirement of inadequate response, intolerance, or contraindication to a 3-month trial of at least one biological disease-modifying antirheumatic drug (DMARD) per SME   |
| March 2019     | Annual review   |
| October 2019   | Revised quantity limit to 90 tablets per 90 days with the addition of 1 mg tablet availability  |
| December 2019  | Annual review. Addition of requirement to trial preferred product   |
| March 2020     | Annual review and reference update  |
| December 2020  | Annual review and reference update. Added Appendix 2 with a list of preferred medications based on diagnosis and plan   |
| June 2021      | Annual review   |
| January 2022   | Added t/f requirement to t/f at least one TNF blocker and added requirement for prescriber to assess risks with malignancy and MACE, per latest PI update   |
| March 2022     | Annual review   |
| May 2022       | COVID-19 added as a new indication per latest PI update. Added statement indicating that the use of Olumiant for COVID-19 must be billed under the medical benefit. Added quantity limit chart statement that the 4 mg tablet is reserved for the treatment of COVID-19 under the medical benefit |
| July 2022      | Per PI update – addition of alopecia areata to criteria noting that it is excluded from coverage  |
| September 2022 | Annual review   |
| September 2023 | Annual review   |
| December 2023  | Annual review   |
| March 2024     | Annual review   |
| September 2024 | Annual review   |
| March 2025     | Annual review   |
| December 2025  | Annual review. Added documentation requirement. Revised Appendix 2. Changed dosing to MDDL  |

## Keywords

---

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on December 12, 2025 and is effective on January 1, 2026.

**Section:** Prescription Drugs **Effective Date:** January 1, 2026  
**Subsection:** Analgesics and Anesthetics **Original Policy Date:** June 22, 2018  
**Subject:** Olumiant **Page:** 8 of 10

### Appendix 1 - List of DMARDs

#### Conventional disease-modifying antirheumatic drugs (DMARDs)

| Generic Name       | Brand Name                  |
|--------------------|-----------------------------|
| azathioprine       | Azasan, Imuran              |
| cyclophosphamide   | Cytoxan                     |
| cyclosporine       | Neoral, Gengraf, Sandimmune |
| hydroxychloroquine | Plaquenil                   |
| leflunomide        | Arava                       |
| methotrexate       | Rheumatrex, Trexall         |
| mycophenolate      | Cellcept                    |
| sulfasalazine      | Azulfidine, Sulfazine       |

#### Biological disease-modifying antirheumatic drugs (DMARDs)

| Generic Name       | Brand Name           |
|--------------------|----------------------|
| abatacept          | Orencia              |
| adalimumab         | Humira               |
| anakinra           | Kineret              |
| bimekizumab-bkzx   | Bimzelx              |
| brodalumab         | Siliq                |
| certolizumab       | Cimzia               |
| etanercept         | Enbrel               |
| golimumab          | Simponi/Simponi Aria |
| guselkumab         | Tremfya              |
| infliximab         | Remicade             |
| infliximab-dyyb    | Zymfentra            |
| ixekizumab         | Taltz                |
| risankizumab-rzaa  | Skyrizi              |
| rituximab          | Rituxan              |
| sarilumab          | Kevzara              |
| secukinumab        | Cosentyx             |
| spesolimab-sbzo    | Spevigo              |
| tildrakizumab-asmn | Illumya              |
| tocilizumab        | Actemra              |
| ustekinumab        | Stelara              |
| vedolizumab        | Entyvio              |

#### Targeted synthetic disease-modifying antirheumatic drugs (DMARDs)

| Generic Name | Brand Name |
|--------------|------------|
| apremilast   | Otezla     |

---

**Section:** Prescription Drugs      **Effective Date:** January 1, 2026  
**Subsection:** Analgesics and Anesthetics      **Original Policy Date:** June 22, 2018  
**Subject:** Olumiant      **Page:** 9 of 10

---

|                 |            |
|-----------------|------------|
| baricitinib     | Olumiant   |
| deucravacitinib | Sotyktu    |
| tofacitinib     | Xeljanz/XR |
| upadacitinib    | Rinvoq     |

## Appendix 2 - List of Preferred Products

List of preferred products:

[https://info.caremark.com/content/dam/enterprise/caremark/microsites/dig/pdfs/pa-fep/fep-misc/FEP\\_IndicationMedChx.pdf](https://info.caremark.com/content/dam/enterprise/caremark/microsites/dig/pdfs/pa-fep/fep-misc/FEP_IndicationMedChx.pdf)

Refer to formulary documents for confirmation of coverage:

<https://www.fepblue.org/pharmacy/prescriptions#drug-lists>